The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports
Article Details
Authors
José Alexandre Mendonça PhD, Guilherme B Damian MD
Article Type
Case Report
DOI
10.7573/dic.212554
Related Articles
- Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries
- Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
- Willingness of European healthcare workers to undergo vaccination against seasonal influenza: current situation and suggestions for improvement
Article Page
Keywords: certolizumab pegol, Doppler ultrasound, gray scale ultrasound, rheumatoid arthritis.
Citation: Mendonça JA, Damian G. The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports. Drugs in Context 2019; 8: 212554. DOI: 10.7573/dic.212554
Contributions: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Disclosure and potential conflicts of interest: JA Mendonça declares no conflicts of interest. G Damian is a full-time employee of UCB, Biopharma S.A., São Paulo, Brazil. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2018/12/dic.212554-COI.pdf
Acknowledgments: Writing assistance was provided to the authors by Robert A Furlong PhD and David P Figgitt PhD, ISMPP CMPP™, Content Ed Net.
Funding declaration: Editorial assistance was provided by Content Ed Net (Brazil) with funding from UCB Biopharma S.A., São Paulo, Brazil. There was no other funding associated with the preparation of this article.
Copyright: Copyright © 2019 Mendonça JA, Damian G. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0, which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
Correct attribution: Copyright © 2019 Mendonça JA, Damian G. https://doi.org/10.7573/dic.212554. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.
Correspondence: José Alexandre Mendonça, Pontifícia Universidade de Campinas, PUCCAMP, Campinas, São Paulo, Brazil. mendoncaja.us@gmail.com
Provenance: submitted; externally peer reviewed.
Submitted: 28 August 2018; Peer review comments to author: 17 October 2018; Revised manuscript received: 11 December 2018; Accepted: 12 December 2018; Publication date: 13 February 2019.
Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.
BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.
For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com
For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com
Download free full text PDF
